TeleManager introduces central IVR system
NEWARK, N.J. TeleManager Technologies will unveil its new Central Interactive Voice Response system at the 2008 National Association of Chain Drug Stores Pharmacy and Technology Conference.
The new system will allow callers to speak their responses into the IVR templated system meaning that, callers can request refills by product name rather than needing to know and key in their prescription number.
The system will also be set-up as a centralized, Windows-based configuration, which will eliminate expensive hardware that would’ve been needed at each individual pharmacy. This will allow the IVR to either be set-up at a pharmacy’s headquarters or TeleManager could host all the functions and then forward the information to the right location.
Additional new features include extensive outbound calling, surveying and marketing functionality. Outbound Refill Reminder and Will-Call Bin pick-up reminder calls will help to improve compliance and improve pharmacy efficiencies. Also, new targeted messaging capabilities can be used to provide specific information to any subset of patients (e.g., first time patients, opt-in customers, specific therapeutic category users, etc.). Likewise, HIPAA compliant opt-in calls allow the pharmacy (centrally or store controlled) to contact segments of its customer base for special services and offers.
InstaClinic temporarily shuts down; in talks with potential partners
ST. LOUIS Less than two years after opening, all four InstaClinic locations have closed, according to the St. Louis Post-Dispatch.
Still, Schnuck Markets, which housed the clinics in its stores, and Patti Sohn, the nurse practitioner who launched them, say they might return.
Sohn described InstaClinic as “in transition” and “restructuring.” She said how many clinics open and their locations will “hinge on continued discussions with Schnucks and our other potential partners.” Sohn said, “Much depends on community need and the physical space available within the various Schnuck markets.”
Michael Juergensmeyer, Schnucks’ vice president of pharmacy, said Sohn, the chain and potential partners are in discussions. He said they’ve spoken with a potential partner interested in opening several clinics in Missouri and another with interest in opening clinics in Illinois.
Merck, Schering-Plough end Claritin-Singulair combo partnership
KENILWORTH and WHITEHOUSE STATION, N.J. Merck and Schering-Plough have withdrawn their application for a combined respiratory drug featuring Schering-Plough’s Claritin and Merck’s Singulair, according to Reuters. This ends an eight-year partnership between the two companies over the proposed drug.
In April, the Food and Drug Administration rejected the combination pill. Both drugs are allergy medications and the companies were hoping that the new combination pill would extend the lucrative franchises.
Claritin is now sold as an over-the-counter allergy treatment and generic versions are available, while asthma-and-allergy drug Singulair was Merck’s biggest-selling product last year with $4.3 billion in sales.
As a result of terminating the respiratory joint venture, Schering expects to receive $105 million from Merck, which Schering will recognize over the remaining three quarters of 2008.